



Financial Tear Sheet

Corporate Profile

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

Stock Information

MYOK (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$55.38
Change (%)	▼ 0.03 (0.05%)
Volume	173,881
52 Week Low	\$32.80
Market Cap	\$2,222,794,369
Rolling EPS	-1.62
PE Ratio	0
Shares Outstanding	40,115,401

Data as of 10/22/18 1:03 p.m. ET



Recent Press Releases

10/22/18


MyoKardia to Host R&D Day on October 30, 2018

09/24/18

MyoKardia to Present at the 2018 Cantor Global Healthcare Conference





























09/20/18













Upcoming Events

 **Tuesday, October 30, 2018 8:00 a.m. ET**
Research and Development (R&D) Day

SEC Filings

<< First | Previous | Next | Last >>

Filing Date	Form	Description	Filing Group	Downloads
10/05/18	4	Statement of changes in beneficial ownership of securities	3,4,5	   
09/24/18	4	Statement of changes in beneficial ownership of securities	3,4,5	   
09/14/18	8-K	Report of unscheduled material events or corporate event	Current Reports	   
09/06/18	4	Statement of changes in beneficial ownership of securities	3,4,5	   
09/06/18	4	Statement of changes in beneficial ownership of securities	3,4,5	   
08/08/18	4	Statement of changes in beneficial ownership of securities	3,4,5	   
08/08/18	10-Q	Quarterly report which provides a	Quarterly	   

		continuing view of a company's financial position	Filings				
08/08/18	8-K	Report of unscheduled material events or corporate event	Current Reports				
07/25/18	4	Statement of changes in beneficial ownership of securities	3,4,5				
07/13/18	SC 13G	A statement of beneficial ownership of common stock by certain persons	Other				

<< First | Previous | Next | Last >>

Corporate Governance

Tassos Gianakakos Chief Executive Officer

Jonathan Fox, M.D., Ph.D. Chief Medical Officer

Jake Bauer Vice President, Business Development and Business Operations

Ingrid Boyes Senior Vice President, Human Resources

Steven Chan Vice President, Corporate Controller

Joseph Lambing, Ph.D. Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell Senior Vice President of Drug Discovery

Iris Roth, Ph.D. Vice President, Program Team Leader